Mark Lubberink

Professor

Uppsala University
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

The PET radioligand [ 11 C]L-deprenyl-D2 binds to monoamine oxidase B (MAO-B), enabling studies of neuroinflammation in various neurological disorders. This study aimed to evaluate non-invasive and parametric methods for quantifying [ 11 C]L-deprenyl-D2 PET. Twenty-eight subjects underwent 60 min dynamic [ 11 C]L-deprenyl-D2 PET. The irreversible binding parameter λ k 3 and the net influx rate relative to the non-displaceable volume of distribution K ND were estimated with an irreversible two-tissue plasma-input compartment model (2T3k). Non-invasive quantification of K ND was performed using cerebellum corrected for specific binding with previously suggested corrections as reference tissue. These corrections were further optimised by comparison to the 2T3k non-displaceable signal in cerebellum. Parametric images were computed using a basis function implementation of the 2T3k model, reference Patlak methods and the reduced reference tissue model. Additionally, a semi-quantitative specific binding index (SBI) was calculated as the ratio of the mean activity concentration at 30–40 or 50–60 min p.i. in target tissues to the peak cerebellum uptake. Parametric λ k 3 images agreed well with VOI-based nonlinear regression. Modified cerebellar reference models and SBI demonstrated poor-to-moderate correlations with arterial input-based analysis and yielded false positive differences in voxel-wise group comparisons. Full kinetic analysis with arterial input is required for accurate assessment of MAO-B activity with [ 11 C]L-deprenyl-D2.

Year:

2026

Year:

2026

Year:

2026

Year:

2024

Background [ 11 C]metomidate, a methyl ester analogue of etomidate, is used for positron emission tomography of adrenocortical cancer, and has been tested in recent clinical trials for lateralization in primary aldosteronism (PA). However, in PA, visualization as well as uptake quantification are hampered by the tracer’s rather high non-specific liver uptake, and its overall clinical usefulness is also limited by the short 20-minute half-life of carbon-11. Therefore, we evaluated para-chloro-2-[ 18 F]fluoroethyl-etomidate, [ 18 F]CETO, a fluorine-18 (T 1/2 =109.8 min) analogue, as a potential new adrenocortical PET tracer. The aim of this study was to assess radiation dosimetry of [ 18 F]CETO. Results [ 18 F]CETO showed a high uptake in adrenal glands, still increasing at 5 h post injection. Adrenal glands (absorbed dose coefficients 0.100 ± 0.032 mGy/MBq in males and 0.124 ± 0.013 mGy/MBq in females) received the highest absorbed dose. The effective dose coefficient was 20 µSv/MBq. Conclusions [ 18 F]CETO has a favourable biodistribution in humans for adrenal imaging. The effective dose for a typical clinical PET examination with 200 MBq [ 18 F]CETO is 4 mSv. Trial registration ClinicalTrials.gov, NCT05361083 Retrospectively registered 29 April 2022. at, URL : https://clinicaltrials.gov/ct2/show/NCT05361083.

Year:

2024

Collaborators (5)

Joachim Burman

Uppsala University

SWEDEN
View details

Teemu Maaniitty

-

FINLAND
View details

Kai Eggers

Uppsala University

SWEDEN
View details

Amirhossein Sanaat

Researcher

University Hospital of Geneva

SWITZERLAND
View details

Juhani Knuuti

-

FINLAND
View details